First Time Loading...
A

AFT Pharmaceuticals Ltd
NZX:AFT

Watchlist Manager
AFT Pharmaceuticals Ltd
NZX:AFT
Watchlist
Price: 2.97 NZD -1% Market Closed
Updated: May 7, 2024
Section:
 

Relative Value

The Relative Value of one AFT stock under the Base Case scenario is 6.56 NZD. Compared to the current market price of 2.97 NZD, AFT Pharmaceuticals Ltd is Undervalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AFT Relative Value
Base Case
6.56 NZD
Undervaluation 55%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

1.8
P/S
P/S
Price to Sales
1.8
vs History
98
vs Industry
58
Median 3Y
2.8
Median 5Y
3.3
Industry
2.5
Forward
1.6
More Details
28.3
P/E
P/E
Price to Earnings
28.3
vs History
68
vs Industry
18
Median 3Y
33.1
Median 5Y
33.8
Industry
23.4
Forward
20
More Details
23.7
P/OCF
P/OCF
Price to OCF
23.7
vs History
98
vs Industry
20
Median 3Y
29.8
Median 5Y
32.7
Industry
17.4
More Details
235.4
P/FCFE
P/FCFE
Price to FCFE
235.4
vs History
12
vs Industry
3
Median 3Y
112.9
Median 5Y
60.2
Industry
23.6
More Details
4.2
P/B
P/B
Price to Book Value
4.2
vs History
98
vs Industry
18
Median 3Y
6.1
Median 5Y
11.3
Industry
2.1
More Details
2
EV/S
EV/S
Enterprise Value to Sales
2
vs History
98
vs Industry
54
Median 3Y
2.8
Median 5Y
3.3
Industry
2.6
Forward
1.8
More Details
4.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.3
vs History
98
vs Industry
48
Median 3Y
6.2
Median 5Y
6.9
Industry
5.2
More Details
17.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.6
vs History
98
vs Industry
23
Median 3Y
20.8
Median 5Y
31.6
Industry
13.7
Forward
13
More Details
17.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
17.6
vs History
98
vs Industry
27
Median 3Y
20.8
Median 5Y
31.6
Industry
17.2
Forward
14.1
More Details
26.1
EV/OCF
EV/OCF
Enterprise Value to OCF
26.1
vs History
96
vs Industry
19
Median 3Y
31.9
Median 5Y
34.2
Industry
16.2
More Details
86.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
86.7
vs History
30
vs Industry
6
Median 3Y
87.5
Median 5Y
60.9
Industry
17.8
More Details
2.8
EV/IC
EV/IC
Enterprise Value to IC
2.8
vs History
98
vs Industry
29
Median 3Y
4
Median 5Y
4.7
Industry
2
More Details

Multiples Across Competitors

AFT Competitors Multiples
AFT Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NZ
AFT Pharmaceuticals Ltd
NZX:AFT
311.5m NZD 1.8 28.3 17.6 17.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
728.7B USD 20.3 118.7 58.1 66.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.3 45.4 33.2 36.2
US
Johnson & Johnson
NYSE:JNJ
357.6B USD 4.2 9.3 11.5 15
US
Merck & Co Inc
NYSE:MRK
323.1B USD 5.3 140.1 34.9 57
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 4.9 37.1 174.2 278
CH
Novartis AG
SIX:NOVN
180.1B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
174.2B CHF 3 15.2 8.6 10.2
US
Pfizer Inc
NYSE:PFE
159B USD 2.9 -514.5 12.8 20.3
P/E Multiple
Earnings Growth
NZ
A
AFT Pharmaceuticals Ltd
NZX:AFT
Average P/E: 50.9
28.3
125%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
118.7
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
45.4
84%
US
Johnson & Johnson
NYSE:JNJ
9.3
-20%
US
Merck & Co Inc
NYSE:MRK
140.1
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.1
168%
CH
Novartis AG
SIX:NOVN
13.4
15%
CH
Roche Holding AG
SIX:ROG
15.2
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -514.5
680%

See Also

Summary
AFT intrinsic value, competitors valuation, and company profile.
DCF Valuation
AFT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AFT stock valuation using valuation multiples.
Wall Street Estimates
AFT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AFT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.